Source: Eur Respir J 2016; 47: 664-667
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Tiberi Simon, D'Ambrosio Lia, De Lorenzo Saverio, Viggiani Pietro, Centis Rosella, Migliori Giovanni Battista. Tuberculosis elimination, patients' lives and rational use of new drugs: revisited. Eur Respir J 2016; 47: 664-667

Member's Comments

No comment yet.

Related content which might interest you: MDR-TB management: what is new? Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination Year: 2012 Rational use of new TB drugs in the EU Source: Annual Congress 2012 - New guidelines in respiratory infections Year: 2012 Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance Source: Eur Respir J 2012; 39: 802-804 Year: 2012 Anti-tuberculosis drugs : what is new? / Nouveaux médicaments antituberculeux: quoi de neuf ? Source: International Congress 2018 – French Programme 2018: Part II Year: 2018 Facts and perspectives in the development of new anti-TB drugs Source: Annual Congress 2008 - New insights into tuberculosis control Year: 2008 Novel drugs against tuberculosis: a clinician's perspective Source: Eur Respir J 2015; 45: 1119-1131 Year: 2015 Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination Source: Eur Respir J 2013; 42: 785-801 Year: 2013 Getting approval for new therapeutic medical devices versus drugs: are the differences justified? Source: Eur Respir Rev 2016; 25: 223-226 Year: 2016 Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges Source: Eur Respir J 2016; 48: 938-943 Year: 2016 The effectiveness of pulmonary TB treatment in patients with organic liver diseases, depending on the way of administration of anti-TB drugs Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016 The paradoxes of asthma management: time for a new approach? Source: Eur Respir J, 50 (3) 1701103; 10.1183/13993003.01103-2017 Year: 2017 Do we need to screen for latent TB when initiating a methotrexate treatment? Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013 Restarting biologic agents in rheumatology patients who developed tuberculosis under TNFα-inhibitor treatment Source: International Congress 2015 – Latent TB infection and screening Year: 2015 Two major problems in TB patients today: MDR and the abandoned therapy Source: Annual Congress 2011 - Challenges in tuberculosis control Year: 2011 Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use Source: Eur Respir J 2014; 43: 289-292 Year: 2004 Tuberculosis and intravenous drug users, impact of proximity measures in screening and treatment Source: International Congress 2015 – Screening strategies in TB Year: 2015 Cleaning agents and asthma: what does the evidence currently tell us about diagnosis and management of these cases? Source: International Congress 2018 – Cleaning agent exposures: are they really harmful to lung health? Year: 2018 Making clinical sense of the explosion in biologics - which drug for which patient and why? Source: International Congress 2019 – PG10 Severe asthma in adults: systematic assessment and biological treatment Year: 2019 Pharmacological treatment optimisation for stable COPD: an endless story? Source: Eur Respir J, 50 (4) 1701250; 10.1183/13993003.01250-2017 Year: 2017